A-166白细胞介素（2,6,10）和血清β -2微球蛋白（Sß2M）在慢性淋巴细胞白血病中的作用

IF 6.3 2区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Clinical chemistry Pub Date : 2025-10-02 DOI:10.1093/clinchem/hvaf086.161

Sudhahar Tamizhan, Rupali Bains, Manisha Naithani, Uttam Nath

{"title":"A-166白细胞介素（2,6,10）和血清β -2微球蛋白（Sß2M）在慢性淋巴细胞白血病中的作用","authors":"Sudhahar Tamizhan, Rupali Bains, Manisha Naithani, Uttam Nath","doi":"10.1093/clinchem/hvaf086.161","DOIUrl":null,"url":null,"abstract":"Background Chronic lymphocytic leukemia (CLL) remains a challenging disease to manage due to its heterogeneous nature and the lack of clarity regarding prognostic markers. This study aimed to clarify cytokine behavior in different stages (Binet and Modified Rai staging) and phases of CLL, particularly focusing on T helper cell dynamics, and investigate their potential as prognostic biomarkers Methods Serum samples from 70 participants were analyzed for levels of cytokines Interleukin IL-2, IL-6, IL-10, and serum beta2 microglobulin (Sß2M) using Sandwich ELISA and Chemiluminescence immunoassay methods. p-value less than 0.05 were considered statistically significant. Ethical approval number: IEC No. AIIMS/IEC/21/700 dated 24/12/2021 Results In present study, 70 CLL patients were included. Median age recorded as 62 years. The proportion of the disease was 2.45 times higher in males. According to Modified Rai and Binet staging, the study participants were classified into low, moderate, or high risk as 17%, 37%, 46%, and 30%, 26%, and 44%, respectively. The mean levels of IL-2, IL-6, IL-10, and serum beta2 microglobulin were 14.09 pg/ml, 42.92 pg/ml, 43.02 pg/ml, and 6.63 ug/L, respectively. Median levels were 7.23 pg/ml for IL-2, 44.74 pg/ml for IL-6, 31.11 pg/ml for IL-10, and 7.29 ug/L for serum beta2 microglobulin. IL-2 positively correlated with hemoglobin and platelet count but negatively correlated with lymphocyte count and serum LDH levels. Conversely, IL-6, IL-10 and Sß2M were positively correlated with lymphocyte count and serum LDH levels but negatively correlated with hemoglobin and platelet count. Comparison across Modified Rai and Binet staging revealed decreasing IL-2 levels (range 35.68pg/ml to 3.55mg/ml, p value 0.00001) and increasing IL-6 (15.05pg/ml to 58.95pg/ml, p value 0.03), IL-10 (2.11pg/ml to 76.11pg/ml, p value 0.00001), and Sß2M values (2.96ug/ml to 8.17ug/ml, p value 0.00001) with disease progression from Low to Intermediate and High risks groups. IL-6 and IL-10 has been found significant positively correlated (p value 0.00001) while IL-2 negatively correlated (p value 0.00001) with Sß2M levels Conclusion Our study found that blood levels of IL-6, IL-10, and Sß2M rose with CLL progression, as did Interleukin-2 in the early stages of the disease and should be evaluated as a novel clinical prognostic marker for predicting early disease load and an aggressive treatment regimen.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"100 1","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A-166 Role of Interleukins (2, 6, 10) and Serum Beta-2 Microglobulin (Sß2M) in Chronic Lymphocytic Leukemia\",\"authors\":\"Sudhahar Tamizhan, Rupali Bains, Manisha Naithani, Uttam Nath\",\"doi\":\"10.1093/clinchem/hvaf086.161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Chronic lymphocytic leukemia (CLL) remains a challenging disease to manage due to its heterogeneous nature and the lack of clarity regarding prognostic markers. This study aimed to clarify cytokine behavior in different stages (Binet and Modified Rai staging) and phases of CLL, particularly focusing on T helper cell dynamics, and investigate their potential as prognostic biomarkers Methods Serum samples from 70 participants were analyzed for levels of cytokines Interleukin IL-2, IL-6, IL-10, and serum beta2 microglobulin (Sß2M) using Sandwich ELISA and Chemiluminescence immunoassay methods. p-value less than 0.05 were considered statistically significant. Ethical approval number: IEC No. AIIMS/IEC/21/700 dated 24/12/2021 Results In present study, 70 CLL patients were included. Median age recorded as 62 years. The proportion of the disease was 2.45 times higher in males. According to Modified Rai and Binet staging, the study participants were classified into low, moderate, or high risk as 17%, 37%, 46%, and 30%, 26%, and 44%, respectively. The mean levels of IL-2, IL-6, IL-10, and serum beta2 microglobulin were 14.09 pg/ml, 42.92 pg/ml, 43.02 pg/ml, and 6.63 ug/L, respectively. Median levels were 7.23 pg/ml for IL-2, 44.74 pg/ml for IL-6, 31.11 pg/ml for IL-10, and 7.29 ug/L for serum beta2 microglobulin. IL-2 positively correlated with hemoglobin and platelet count but negatively correlated with lymphocyte count and serum LDH levels. Conversely, IL-6, IL-10 and Sß2M were positively correlated with lymphocyte count and serum LDH levels but negatively correlated with hemoglobin and platelet count. Comparison across Modified Rai and Binet staging revealed decreasing IL-2 levels (range 35.68pg/ml to 3.55mg/ml, p value 0.00001) and increasing IL-6 (15.05pg/ml to 58.95pg/ml, p value 0.03), IL-10 (2.11pg/ml to 76.11pg/ml, p value 0.00001), and Sß2M values (2.96ug/ml to 8.17ug/ml, p value 0.00001) with disease progression from Low to Intermediate and High risks groups. IL-6 and IL-10 has been found significant positively correlated (p value 0.00001) while IL-2 negatively correlated (p value 0.00001) with Sß2M levels Conclusion Our study found that blood levels of IL-6, IL-10, and Sß2M rose with CLL progression, as did Interleukin-2 in the early stages of the disease and should be evaluated as a novel clinical prognostic marker for predicting early disease load and an aggressive treatment regimen.\",\"PeriodicalId\":10690,\"journal\":{\"name\":\"Clinical chemistry\",\"volume\":\"100 1\",\"pages\":\"\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/clinchem/hvaf086.161\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/clinchem/hvaf086.161","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

慢性淋巴细胞白血病（CLL）由于其异质性和缺乏明确的预后标志物，仍然是一种具有挑战性的疾病。本研究旨在阐明细胞因子在CLL不同分期（Binet分期和Modified Rai分期）和分期的行为，特别关注T辅助细胞动力学，并探讨其作为预后生物标志物的潜力。方法采用Sandwich ELISA和化学发光免疫分析法分析70名参与者的血清样本中细胞因子白介素IL-2、IL-6、IL-10和血清β 2微球蛋白（Sß2M）的水平。p值小于0.05认为有统计学意义。伦理批准号：IECAIIMS/IEC/21/700日期为2021年12月24日结果本研究纳入70例CLL患者。中位年龄为62岁。男性患此病的比例是男性的2.45倍。根据Modified Rai和Binet分期，研究参与者分别被分为低、中、高风险，分别为17%、37%、46%、30%、26%和44%。血清中IL-2、IL-6、IL-10和β 2微球蛋白的平均水平分别为14.09 pg/ml、42.92 pg/ml、43.02 pg/ml和6.63 ug/L。IL-2的中位水平为7.23 pg/ml， IL-6为44.74 pg/ml， IL-10为31.11 pg/ml，血清β 2微球蛋白为7.29 ug/L。IL-2与血红蛋白和血小板计数呈正相关，与淋巴细胞计数和血清LDH水平呈负相关。相反，IL-6、IL-10和Sß2M与淋巴细胞计数和血清LDH水平呈正相关，与血红蛋白和血小板计数负相关。改良Rai和Binet分期的比较显示，随着低、中、高风险组疾病进展，IL-2水平降低（范围为35.68pg/ml至3.55mg/ml， p值0.00001），IL-6 （15.05pg/ml至58.95pg/ml， p值0.03）、IL-10 （2.11pg/ml至76.11pg/ml， p值0.00001）和Sß2M值（2.96ug/ml至8.17ug/ml， p值0.00001）升高。IL-6和IL-10已被发现与Sß2M水平呈显著正相关（p值0.00001），而IL-2与Sß2M水平呈显著负相关（p值0.00001）。结论我们的研究发现，随着CLL的进展，血液中IL-6、IL-10和Sß2M水平升高，白细胞介素-2在疾病的早期阶段也升高，应被评估为预测早期疾病负荷和积极治疗方案的一种新的临床预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A-166 Role of Interleukins (2, 6, 10) and Serum Beta-2 Microglobulin (Sß2M) in Chronic Lymphocytic Leukemia

Background Chronic lymphocytic leukemia (CLL) remains a challenging disease to manage due to its heterogeneous nature and the lack of clarity regarding prognostic markers. This study aimed to clarify cytokine behavior in different stages (Binet and Modified Rai staging) and phases of CLL, particularly focusing on T helper cell dynamics, and investigate their potential as prognostic biomarkers Methods Serum samples from 70 participants were analyzed for levels of cytokines Interleukin IL-2, IL-6, IL-10, and serum beta2 microglobulin (Sß2M) using Sandwich ELISA and Chemiluminescence immunoassay methods. p-value less than 0.05 were considered statistically significant. Ethical approval number: IEC No. AIIMS/IEC/21/700 dated 24/12/2021 Results In present study, 70 CLL patients were included. Median age recorded as 62 years. The proportion of the disease was 2.45 times higher in males. According to Modified Rai and Binet staging, the study participants were classified into low, moderate, or high risk as 17%, 37%, 46%, and 30%, 26%, and 44%, respectively. The mean levels of IL-2, IL-6, IL-10, and serum beta2 microglobulin were 14.09 pg/ml, 42.92 pg/ml, 43.02 pg/ml, and 6.63 ug/L, respectively. Median levels were 7.23 pg/ml for IL-2, 44.74 pg/ml for IL-6, 31.11 pg/ml for IL-10, and 7.29 ug/L for serum beta2 microglobulin. IL-2 positively correlated with hemoglobin and platelet count but negatively correlated with lymphocyte count and serum LDH levels. Conversely, IL-6, IL-10 and Sß2M were positively correlated with lymphocyte count and serum LDH levels but negatively correlated with hemoglobin and platelet count. Comparison across Modified Rai and Binet staging revealed decreasing IL-2 levels (range 35.68pg/ml to 3.55mg/ml, p value 0.00001) and increasing IL-6 (15.05pg/ml to 58.95pg/ml, p value 0.03), IL-10 (2.11pg/ml to 76.11pg/ml, p value 0.00001), and Sß2M values (2.96ug/ml to 8.17ug/ml, p value 0.00001) with disease progression from Low to Intermediate and High risks groups. IL-6 and IL-10 has been found significant positively correlated (p value 0.00001) while IL-2 negatively correlated (p value 0.00001) with Sß2M levels Conclusion Our study found that blood levels of IL-6, IL-10, and Sß2M rose with CLL progression, as did Interleukin-2 in the early stages of the disease and should be evaluated as a novel clinical prognostic marker for predicting early disease load and an aggressive treatment regimen.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical chemistry 医学-医学实验技术

CiteScore

11.30

自引率

4.30%

发文量

212

审稿时长

1.7 months

期刊介绍： Clinical Chemistry is a peer-reviewed scientific journal that is the premier publication for the science and practice of clinical laboratory medicine. It was established in 1955 and is associated with the Association for Diagnostics & Laboratory Medicine (ADLM). The journal focuses on laboratory diagnosis and management of patients, and has expanded to include other clinical laboratory disciplines such as genomics, hematology, microbiology, and toxicology. It also publishes articles relevant to clinical specialties including cardiology, endocrinology, gastroenterology, genetics, immunology, infectious diseases, maternal-fetal medicine, neurology, nutrition, oncology, and pediatrics. In addition to original research, editorials, and reviews, Clinical Chemistry features recurring sections such as clinical case studies, perspectives, podcasts, and Q&A articles. It has the highest impact factor among journals of clinical chemistry, laboratory medicine, pathology, analytical chemistry, transfusion medicine, and clinical microbiology. The journal is indexed in databases such as MEDLINE and Web of Science.